Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1

Status

Completed 1Active not recruiting 1

Sponsor Class

OTHER 3INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Dermatologic 2

Conditions

Melanoma 1103Carcinoma, Non-Small-Cell Lung 281Neoplasms 199Keratosis, Actinic 181Carcinoma, Renal Cell 162Skin Neoplasms 143Colorectal Neoplasms 142Neoplasm Metastasis 140Squamous Cell Carcinoma of Head and Neck 134Breast Neoplasms 118Ovarian Neoplasms 114Carcinoma, Basal Cell 97Stomach Neoplasms 94Pancreatic Neoplasms 93Lung Neoplasms 91Head and Neck Neoplasms 90Lymphoma, T-Cell, Cutaneous 88Uterine Cervical Neoplasms 75Triple Negative Breast Neoplasms 74Sarcoma 68Carcinoma, Hepatocellular 67Prostatic Neoplasms 65Uveal Melanoma 64Carcinoma, Merkel Cell 64Urinary Bladder Neoplasms 63Esophageal Neoplasms 61Carcinoma, Transitional Cell 57Lymphoma 55Endometrial Neoplasms 55Small Cell Lung Carcinoma 52

Interventions

cemiplimab 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
INDUSTRY × Cutaneous Squamous Cell Carcinoma × Dermatologic × Clear all
NCT03969004 2026-03-27

Study of Adjuvant Cemiplimab Versus Placebo After Surgery and Radiation Therapy in Patients With High Risk Cutaneous Squamous Cell Carcinoma

Regeneron Pharmaceuticals

Phase 3 Active not recruiting
415 enrolled 1 FDA
Dermatologic

Cutaneous Squamous Cell Carcinoma

NCT04154943 2025-12-23

Study of Cemiplimab in Patients With Type of Skin Cancer Stage II to IV Cutaneous Squamous Cell Carcinoma

Regeneron Pharmaceuticals

Phase 2 Completed
79 enrolled 16 charts
Dermatologic

Cutaneous Squamous Cell Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡